We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
President and CEO, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC; CYCCP), a late-stage, cancer drug development company based in Scotland and New Jersey, since 1996 when it began operations. Over 34 years, at three publicly-held biotechs and two pharmas, participated in several drug programs that reached the market, mainly in inflammation and hematology/oncology. Previously a Vice President and Managing Director, Europe at Liposome (subsequently acquired by Elan) and a Vice President at Bristol-Myers Squibb, he began his career in the early ’80s, after training at Novartis, as one of the first employees of Centocor (a pioneering biopharmaceutical company subsequently acquired by Johnson & Johnson). MBA and MPH with honors, Kellogg School of Management, Northwestern University and BA, Williams College. Serves on the Board of Trustees of BioNJ, the NJ biotech association.
This speaker's sessions: